India, Oct. 26 -- Xencor, Inc. (XNCR) is up 23.87 percent, gaining $6.01 to $31.19 on Monday. The surge appears to follow positive clinical data announced Sunday for XmAb819, the company's investigational ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma. Xencor presented updated Phase 1 results at the ESMO Congress 2026 and reported additional data supporting 400 mcg/kg as the proposed recommended Phase 3 intravenous dose.
Xencor is currently trading at $31.19, up from the previous close of $25.18 after opening at $32.25 on the Nasdaq. The stock has traded between $28.93 and $33.58 during the session, with the intraday high also marking a new 52-week high. Trading volume stands at 4...